mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 Trial

A combination of a personalized vaccine and the existing immunotherapy drug Keytruda has shown early signs of keeping high-risk melanoma from returning after surgery, according to announcements from Merck and Moderna. The companies reported that patients who received both treatments stayed cancer-free longer than those on Keytruda alone and faced a lower chance of the disease spreading. The phase three trial included more than one thousand participants with stage two, three, or four melanoma.

The vaccine, known as Intismeran, is tailored to each patient's tumor and targets specific mutations. It was administered after surgery to remove the cancer. Company statements described the results as significant, yet they stopped short of detailing how much time was gained or whether the benefit holds beyond the initial follow-up period. Full trial data has not been released or reviewed by outside experts.

Cancer specialists described the approach as interesting but stressed the need for caution. National Clinical Director for Cancer at NHS England Prof Peter Johnson called the development exciting during a radio appearance, while noting that past immune therapies have produced mixed long-term outcomes. Independent review and regulatory approval would still be required before any wider use, a process that can take years even after positive early signals.

This latest announcement comes from the same companies that promoted mRNA technology during the COVID period, when public trust in rapid vaccine rollouts fractured along political lines. Moderna in particular saw its stock move on the news, reflecting investor interest in new applications for the platform. Critics have long argued that financial incentives can encourage companies to highlight promising snapshots while downplaying side effects or durability issues that surface later.

The trial focused on patients already at elevated risk, meaning the findings may not translate directly to lower-risk cases or other cancer types. Experts also point out that combining the vaccine with an established drug like Keytruda makes it harder to isolate the new treatment's exact contribution. No information has surfaced yet on manufacturing costs, availability timelines, or whether the approach would reach patients outside elite trial centers.

Past cancer vaccine efforts have generated similar early enthusiasm only to encounter setbacks in larger studies. Regulators will examine safety data across the full participant group, including any immune-related reactions that can accompany these therapies. For now, the results remain preliminary despite the optimistic tone from the manufacturers.